Pharvaris N.V.
corporate_fare Company Profile
Pharvaris N.V. (NASDAQ:PHVS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for PHVS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for PHVS spans 6-K, 144, 424B5, 20-F.
Recent high-impact activity:
- Pharvaris Q3 2026: €283M Cash, Loss Widens to €47.4M Ahead of April 2027 PDUFA
- Pharvaris' Deucrictibant Phase 3 Data Published in The Lancet, Showing Rapid HAE Attack Resolution
- Pharvaris Officer/Director Schikan Files to Sell 200,000 Shares Worth $7M
- Pharvaris Insider Schoodic Management BV Files to Sell 300,000 Shares Worth $10.5M
- Pharvaris CHAPTER-3 Data: 83% Attack Reduction, All Secondary Endpoints Met
Financial Snapshot
Short Interest & Short Volume
3.58 days to coverFINRA reported short interest of 2,539,475 shares in PHVS as of the October 30, 2026 settlement, a 3.0% increase from the prior period — about 3.6 days to cover at its recent average daily volume. On November 20, 2026, 36.5% of PHVS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
PHVS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.